Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Operating Expenses (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Operating Expenses for 16 consecutive years, with $11.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 19.23% to $11.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $100.0 million, a 58.72% increase, with the full-year FY2024 number at $61.0 million, down 4.99% from a year prior.
  • Operating Expenses was $11.8 million for Q3 2025 at Harvard Bioscience, down from $12.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $61.9 million in Q1 2025 to a low of $11.8 million in Q3 2025.
  • A 5-year average of $18.1 million and a median of $15.9 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: dropped 27.49% in 2023, then surged 262.75% in 2025.
  • Harvard Bioscience's Operating Expenses stood at $17.9 million in 2021, then dropped by 8.8% to $16.3 million in 2022, then fell by 1.52% to $16.0 million in 2023, then dropped by 12.73% to $14.0 million in 2024, then decreased by 15.54% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Operating Expenses are $11.8 million (Q3 2025), $12.4 million (Q2 2025), and $61.9 million (Q1 2025).